null

null

null

null

null

null

null

null

null

Minimal long-term debt; primarily equity-financed clinical-stage biotech; 20% rate rise has negligible direct interest cost impact

Higher rates increase equity dilution cost and reduce biotech valuations; GENELUX faces elevated capital-raise pressure in tight-rate environments

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Viral vector manufacturing capacity (limited CDMOs globally) and specialized cell-culture reagents concentrated in US/EU suppliers

Minimal international commercial revenue currently; currency devaluation exposure is negligible given US-centric clinical operations

Primarily US-based operations and clinical trials; limited exposure to sovereign currency risk in international markets at this stage

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Single CDMO dependency for Vaccinia virus manufacturing likely exceeds 30% of operational input; highly non-substitutable short-term

Clinical-stage biotech; cloud infrastructure termination would disrupt data analytics and trial management but not core drug manufacturing

Secondary impact on regulatory submission systems and bioinformatics pipelines; 30-day migration window is operationally stressful but survivable

Low cloud API coupling risk; primary operational dependencies are wet-lab and manufacturing, not software API integrations

Revenue model is drug sales/licensing, not investment contracts; Howey Test risk is not applicable to core business model

Very High

Clinical trial patient data subject to HIPAA; limited GDPR exposure from EU trial sites; CCPA exposure minimal given no consumer-facing data product

Low antitrust risk; single-product oncology biotech with no dominant market position; no platform or pricing power to attract regulatory scrutiny

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Pre-commercial; 100% transactional/grant/licensing revenue potential; no recurring subscription revenue currently exists

Future monetization via drug sales (Olvi-Vec) and potential licensing/partnership deals with larger oncology-focused pharma companies

Oncology drug pricing subject to Medicare negotiation pressure and competitive PD-1/VEGF landscape; pricing power moderate if Phase 3 data strong

Moderate; differentiated oncolytic virus mechanism but faces pricing ceiling from existing checkpoint inhibitor benchmarks (~$150K-$200K/year)

Biopharmaceutical gross margins typically 70-85% at commercial scale; GENELUX targets similar bracket post-launch if manufacturing scales

No free-rider risk; prescription oncology drug with no digital or open-access component; patient retention driven by clinical efficacy

Revenue growth sublinear to headcount post-commercialization; manufacturing scale-up is capital-intensive not headcount-intensive

Marginal cost of growth declines post-approval; incremental revenue from additional indications leverages existing manufacturing and SG&A base

Not applicable; GENELUX operates no franchise network

At 10x scale, oncologist adoption and hospital formulary inclusion are key CAC drivers; CAC likely falls as brand recognition grows post-approval

No meaningful network effects; drug efficacy does not improve with more users; adoption driven by clinical evidence, not user base size

AI displacement risk low for core drug manufacturing; AI may enhance trial design and biomarker analysis but does not threaten primary asset

Moderate-high recession resistance; late-stage cancer treatment demand is inelastic; however, fundraising and partnership deals suffer in downturns

Oncologists and hospital systems treating platinum-resistant ovarian cancer; highly concentrated in academic medical centers and cancer centers

Health insurers and government payers (Medicare/Medicaid) as critical secondary segment controlling reimbursement access and volume

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

13725.0% CapEx / Revenue (High-CapEx Infrastructure)

0001231457

GNLX